The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

In a major positive step for global respiratory health, Member States at the 78th World Health Assembly (WHA), held May 19–27 ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

Understanding the differences between colds, flu, and RSV can help in identifying the illness you're dealing with, the ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering their first RSV season.

FEV1/FVC was significantly lower in young adults who had severe bronchiolitis during infancy vs those who did not. Severe bronchiolitis during infancy may contribute to irreversible airway obstruction ...

In recent weeks, Health and Human Services Secretary Robert F. Kennedy Jr. has begun to dismantle decades of vaccine safety ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...